Hacking Immune Cells To Expand Their Therapeutic Potential
In the Roybal Lab, we harness the tools of synthetic and chemical biology to enhance the therapeutic potential of engineered immune cells. We take a comprehensive approach to cellular engineering by developing new synthetic receptors, signal transduction cascades, and cellular response programs to enhance the safety and effectiveness of adoptive cell therapies. We also study the logic of natural cellular signaling systems, and the underlying principles of cellular communication and collective cell behavior during an immune response. These interests are complementary as cell engineering is often informed by knowledge obtained from studying natural mechanisms of cell regulation refined by evolution.
The Roybal Lab is a dedicated group of students, post-docs, physicians, and staff scientists with diverse backgrounds ranging from basic science to cellular engineering and synthetic immunology. Each member brings expertise in their field to our unique and highly collaborative research environment.
Media highlights of Roybal Lab's research.
Recent Lab News
The Roybal lab is looking for Postdocs and Staff Scientist to join our team! We are starting a number of new and exciting synthetic biology and cell therapy projects that you can be a part of. Things are moving fast, please get in touch with us by emailing your CV, including references and a brief statement of interest.
We are excited to share our latest paper published in Cell! Congratulations to Ray Liu and Iowis Zhu for leading the development of clinically optimized and tunable nextgen synNotch receptors (dubbed SNIPRs) for cell therapies. This was a major effort involving many members of lab including Julie, Axel, Dan P., and Josef.
It’s always fun to see new faces in the lab and this February we added two more members to our ranks. Panagiotis Christopoulos and Maria Jose “Majo” Duran are officially in!
This month we welcome Max Foisey as a new rotation student. Max’s previous work at Intellia Therapeutics focused on using CRISPR to generate immune cell therapies. During his rotation in the Roybal Lab he’ll be working with Julie Garcia, using novel receptors to augment T cell signaling in-vitro and in-vivo.